HTDS Hard to Treat Diseases Inc. - 500 Beiträge pro Seite
eröffnet am 17.03.11 17:13:03 von
neuester Beitrag 18.03.11 13:05:06 von
neuester Beitrag 18.03.11 13:05:06 von
Beiträge: 6
ID: 1.164.761
ID: 1.164.761
Aufrufe heute: 0
Gesamt: 275
Gesamt: 275
Aktive User: 0
ISIN: US41164A1034 · WKN: 812965 · Symbol: HTDS
0,0000
USD
0,00 %
0,0000 USD
Letzter Kurs 14.06.24 Nasdaq OTC
Neuigkeiten
TitelBeiträge |
---|
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
323,60 | +17,59 | |
5,3700 | +15,98 | |
449,10 | +15,09 | |
16,640 | +14,68 | |
4,6050 | +12,04 |
Wertpapier | Kurs | Perf. % |
---|---|---|
10,490 | -13,16 | |
2,1000 | -16,00 | |
7,1900 | -20,02 | |
0,9500 | -22,76 | |
80,22 | -23,42 |
Mellow Hope (HTDS) Seminar for Indian Medical Experts to Discuss Cerebroprotein Hydrolysate
Mar 3, 2011 3:45:00 PM
Close Ad
Email story | Discuss on ZenoBank | View more ads
SHENZEN, CHINA -- (MARKET WIRE) -- 03/03/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced today that its China-based Shenzhen Mellow Hope subsidiary is planning a seminar for Indian medical experts.
The Indian experts are expected in China for the seminar and will visit Chinese medical experts in Beijing, Shanghai and Shenzhen. They will discuss plans to market 'Cognistar' (Cerebroprotein Hydrolysate for Injection) in India. Mellow Hope believes that this product will receive wide acceptance in the Indian market and has huge growth potential.
Mellow Hope finished the clinical trials of Cerebroprotein Hydrolysate for Injection in India. This biological product is a unique nutriment for the brain that helps the central nervous system in multiple ways, including: regulating and improving nerve cell metabolism; promoting synapse generation; inducing nerve cell differentiation; and protecting nerve cells against damages by ischemia and neurotoxins.
Mellow Hope looks forward to the visit from the Indian medical experts and plans to update investors as these developments progress.
Mellow Hope (HTDS) Reaches a Milestone in Indonesia
Mar 8, 2011 3:45:00 PM
Close Ad
Email story | Discuss on ZenoBank | View more ads
SHENZEN, CHINA -- (MARKET WIRE) -- 03/08/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based subsidiary Shenzhen Mellow Hope has been inspected by the Indonesian Muslim Association and been issued a HALAL certificate.
The Indonesian Muslim Association inspected the Mellow Hope plant that produces the ACYW135 and A+C Meningococcal Polysaccharide vaccines. Mellow Hope plant and method of production of these vaccines met the HALAL certificate (Halal Assurance System) requirements. The Indonesian Muslim Association is well-known and regarded as the most authoritative Muslim organization in the world. The HALAL is a difficult certificate to receive, and Mellow Hope believes that there are only two companies in the world that have obtained this certificate.
With the HALAL certificate in hand, Mellow Hope believes that it will have advantage in marketing its MEVAC-ACYW and A+C in Indonesia and other Muslim countries. Mellow Hope is participating in tenders of Group ACYW135 in Indonesia and Bangladesh, and believes that the ability to acquire HALAL certificate will be a great help in securing the tenders.
Mellow Hope (HTDS) Increases Indian Vaccine Sales
Mar 16, 2011 2:45:00 PM
Close Ad
Email story | Discuss on ZenoBank | View more ads
SHENZHEN, CHINA -- (MARKET WIRE) -- 03/16/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary had a major leap in sales volume for its Hepatitis A (MEVAC-A) vaccine in India in 2010 compared to a year earlier.
Mellow Hope launched the Hepatitis A vaccine in India at the end of 2005, and its high quality and competitive pricing has enabled it to steadily increase its market share year by year. MEVAC-A has been embraced by Indian doctors and patients in need of the vaccine, which has given Mellow Hope a very good reputation in the country.
Mellow Hope believes that it can capitalize on the success and wide acceptance of MEVAC-A and create more business opportunities in India, which should increase profits for HTDS and add value for shareholders.
Mellow Hope (HTDS) Two Vaccines Approved in Pakistan
Mar 17, 2011 10:00:00 AM
Close Ad
Email story | Discuss on ZenoBank | View more ads
SHENZHEN, CHINA -- (MARKET WIRE) -- 03/17/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary has had two vaccines for contagious diseases approved by Pakistan's Ministry of Health to be sold in the country.
It has taken several years of continuous efforts by Mellow Hope to have Hepatitis A Live Attenuated Vaccine (MEVAC-A) and Influenza Virus Vaccine, Inactivated (Split) (MEVAC-FLU) approved for use in Pakistan. The company is setting prices for the vaccines in anticipation of receiving registration certificates that will allow it to start taking orders.
Mellow Hope believes that the two vaccines will be launched successfully and become widely accepted by those who need them among Pakistan's 190 million residents. Improved performance in the world's sixth most populated country, where Hepatitis is a highly infectious and problematic disease, should increase profits for HTDS and add value for shareholders.
Mar 3, 2011 3:45:00 PM
Close Ad
Email story | Discuss on ZenoBank | View more ads
SHENZEN, CHINA -- (MARKET WIRE) -- 03/03/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced today that its China-based Shenzhen Mellow Hope subsidiary is planning a seminar for Indian medical experts.
The Indian experts are expected in China for the seminar and will visit Chinese medical experts in Beijing, Shanghai and Shenzhen. They will discuss plans to market 'Cognistar' (Cerebroprotein Hydrolysate for Injection) in India. Mellow Hope believes that this product will receive wide acceptance in the Indian market and has huge growth potential.
Mellow Hope finished the clinical trials of Cerebroprotein Hydrolysate for Injection in India. This biological product is a unique nutriment for the brain that helps the central nervous system in multiple ways, including: regulating and improving nerve cell metabolism; promoting synapse generation; inducing nerve cell differentiation; and protecting nerve cells against damages by ischemia and neurotoxins.
Mellow Hope looks forward to the visit from the Indian medical experts and plans to update investors as these developments progress.
Mellow Hope (HTDS) Reaches a Milestone in Indonesia
Mar 8, 2011 3:45:00 PM
Close Ad
Email story | Discuss on ZenoBank | View more ads
SHENZEN, CHINA -- (MARKET WIRE) -- 03/08/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based subsidiary Shenzhen Mellow Hope has been inspected by the Indonesian Muslim Association and been issued a HALAL certificate.
The Indonesian Muslim Association inspected the Mellow Hope plant that produces the ACYW135 and A+C Meningococcal Polysaccharide vaccines. Mellow Hope plant and method of production of these vaccines met the HALAL certificate (Halal Assurance System) requirements. The Indonesian Muslim Association is well-known and regarded as the most authoritative Muslim organization in the world. The HALAL is a difficult certificate to receive, and Mellow Hope believes that there are only two companies in the world that have obtained this certificate.
With the HALAL certificate in hand, Mellow Hope believes that it will have advantage in marketing its MEVAC-ACYW and A+C in Indonesia and other Muslim countries. Mellow Hope is participating in tenders of Group ACYW135 in Indonesia and Bangladesh, and believes that the ability to acquire HALAL certificate will be a great help in securing the tenders.
Mellow Hope (HTDS) Increases Indian Vaccine Sales
Mar 16, 2011 2:45:00 PM
Close Ad
Email story | Discuss on ZenoBank | View more ads
SHENZHEN, CHINA -- (MARKET WIRE) -- 03/16/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary had a major leap in sales volume for its Hepatitis A (MEVAC-A) vaccine in India in 2010 compared to a year earlier.
Mellow Hope launched the Hepatitis A vaccine in India at the end of 2005, and its high quality and competitive pricing has enabled it to steadily increase its market share year by year. MEVAC-A has been embraced by Indian doctors and patients in need of the vaccine, which has given Mellow Hope a very good reputation in the country.
Mellow Hope believes that it can capitalize on the success and wide acceptance of MEVAC-A and create more business opportunities in India, which should increase profits for HTDS and add value for shareholders.
Mellow Hope (HTDS) Two Vaccines Approved in Pakistan
Mar 17, 2011 10:00:00 AM
Close Ad
Email story | Discuss on ZenoBank | View more ads
SHENZHEN, CHINA -- (MARKET WIRE) -- 03/17/11 -- Hard to Treat Diseases, Inc. (PINK SHEETS: HTDS) (www.htdsmedical.com) announced that its China-based Shenzhen Mellow Hope subsidiary has had two vaccines for contagious diseases approved by Pakistan's Ministry of Health to be sold in the country.
It has taken several years of continuous efforts by Mellow Hope to have Hepatitis A Live Attenuated Vaccine (MEVAC-A) and Influenza Virus Vaccine, Inactivated (Split) (MEVAC-FLU) approved for use in Pakistan. The company is setting prices for the vaccines in anticipation of receiving registration certificates that will allow it to start taking orders.
Mellow Hope believes that the two vaccines will be launched successfully and become widely accepted by those who need them among Pakistan's 190 million residents. Improved performance in the world's sixth most populated country, where Hepatitis is a highly infectious and problematic disease, should increase profits for HTDS and add value for shareholders.
0.0002-0.0003
vol.91,000,000
vol.91,000,000
es gab auch schon vorher jede Menge interessante Meldungen, aber der Kurs kennt nur die Richtung nach unten.
Bei den derzeitigen Kursen kann es zwar kaum noch runter gehen, aber darauf verlassen kann man sich auch nicht.
Ich denke, einen Zock ist es wert.
Bei den derzeitigen Kursen kann es zwar kaum noch runter gehen, aber darauf verlassen kann man sich auch nicht.
Ich denke, einen Zock ist es wert.
ja das ist OTC
nur für zocker geeignet
0.0002-0.0003 vol.100,000,000
nur für zocker geeignet
0.0002-0.0003 vol.100,000,000
könnte dilution dahinter stecken
passt auf
0.0002-0.0003 vol. 160,000,000
passt auf
0.0002-0.0003 vol. 160,000,000
vielleicht sollte man noch erste Umsatz- und Gewniizahlen abwarten
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
0,00 | |
0,00 | |
+100,00 | |
- | |
0,00 | |
- | |
0,00 | |
0,00 | |
0,00 | |
+9,09 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
58 | ||
40 | ||
22 | ||
22 | ||
19 | ||
17 | ||
17 | ||
16 | ||
15 | ||
14 |